Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Q2 2025 · 10-Q
Revenue$7.08B$7.08B+1.8% vs Q2 2024 Net Income$1.96B$1.96B+21.4% vs Q2 2024 EPS Diluted$1.56$1.56+20.9% vs Q2 2024 Operating Income$2,474,000,000−6.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$720,000,000−39.7% Margins · derivedOperating margin34.9%−3.1 pt vs Q2 2024
Net margin27.7%+4.5 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end